Icaritin Phase I data presented at 2013 ASCO Annual Meeting: June 3rd, 2013
Icaritin Ph I interim results were first presented at the 49th American Society of Clinical Oncology on June 3rd in Chicago. The results were presented as a poster with the title of “The first-in-human phase I study of ER-α36 modulator icaritin in patients with advanced solid tumors (ASCO 2013, Abstract ID 2614)”. According to the data presented, icaritin demonstrated a very favorable safety profile in breast and hepatocellular carcinoma (HCC) patients and emerging clinical efficacy signal is also very encouraging. “With the positive clinical signals, we will initiate our POC study in HCC next quarter”, Dr. Meng, company Chairman and CEO says, “At the same time, Shenogen is actively seeking a global development and commercialization partner to bring icaritin to worldwide patients that could benefit from icaritin and other ER-α36 modulators in our pipeline.” For further information, please contact Chief Business Officer Jun Bao at jun.bao@shenogen.com